%0 Journal Article %T How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team %A Zhang, Yalei %A Shen, Jianfei %A Simone II, Charles B. %A Cappuzzo, Federico %A Fong, Kwun M. %A Rosell, Rafael %A Chang, Joe Y. %A Ampollini, Luca %A Choi, J. Isabelle %A He, Jianxing %A Jiang, Tao %A Lung Cancer Cooperative Group, Written on behalf of AME %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team %K %X Although most patients with stage I non-small cell lung cancer (NSCLC) can achieve long-term survival, some still remain at high risk of relapse (1-3). The excellent outcomes and increasing use of stereotactic ablative radiotherapy (SABR) for stage I NSCLC has recently posed a challenge to surgery (4,5). Nevertheless, lobectomy with mediastinal lymph node dissection or sampling has remained the standard of care for operable, stage I NSCLC. %U https://jtd.amegroups.org/article/view/22209 %V 10 %N 6 %P 3883-3890 %@ 2077-6624